On May 26, 2023 Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for unmet medical needs, reported its expansion in Oncology with its first-in-class four-in-one Bacterial Cell and Gene Therapy AUP-55 (Press release, Aurealis Therapeutics, MAY 26, 2023, View Source [SID1234632136]). The company’s first abstract, Effect of multi-targeting bacterial gene therapy on tumor regression and survival in mouse models of ovarian and intraperitoneal cancer, has been accepted and published on the prestigious American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This moment marks a pivotal turning point for Aurealis Therapeutics, as the company expands from its acclaimed focus on chronic wounds into the field of oncology and creates therapeutic solutions such as AUP-55 for ovarian, intraperitoneal or bladder cancer. The Aurealis Therapeutics Team is proud for the publication of its first abstract as it prepares for its participation in the ASCO (Free ASCO Whitepaper) Annual Meeting which will take place from 2-6 June in Chicago, IL.